Obefazimod

7 trials 1 recruiting

Filter these 7 trials by condition, phase, country and more.

Open in Search →

7 Registered trials

1 Recruiting

3 Completed trials

1 Sponsors

19 Countries

Phase III

Phase II

Phase III: 5 Phase II: 2

Indications tested

Colitis ulcerative 5 Crohn's disease 1

Sponsors using this IMP

All trials

7 total

ABTECT-1 – ABX464 Treatment Evaluation for ulcerative Colitis Therapy -1 Not authorised

2022-500535-36-00 Phase III 6 countries Abivax
ABTECT-2 – ABX464 Treatment Evaluation for ulcerative Colitis Therapy -2 Not authorised

2022-500536-11-00 Phase III 6 countries Abivax
ABTECT-Maintenance – ABX464 Treatment Evaluation for ulcerative Colitis Therapy Not authorised

2022-500537-84-00 Phase III 6 countries Abivax
Efficacy and Safety of Obefazimod in Subjects With Moderately to Severely Active Crohn's Disease ( ENHANCE-CD ) Recruiting

2023-508234-34-00 Phase II 11 countries Abivax
Effects of ABX464 during long-term treatment in patients with moderate to severe ulcerative colitis Ended

2023-507974-42-00 Phase II 11 countries Abivax
ABTECT-1 – ABX464 Treatment Evaluation for ulcerative Colitis Therapy -1 Ended

2022-500535-36-01 Phase III 13 countries Abivax
ABTECT-2 – ABX464 Treatment Evaluation for ulcerative Colitis Therapy -2 Ended

2022-500536-11-01 Phase III 14 countries Abivax

Showing 1–7 of 7 trials

← All drugs A–Z